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Abstract: Patients with chronic obstructive pulmonary disease (COPD) exhibit dominant 
features of chronic bronchitis, emphysema, and/or asthma, with a common phenotype of 
airflow obstruction. COPD pulmonary physiology reflects the sum of pathological changes 
in COPD, which can occur in large central airways, small peripheral airways, and the lung 
parenchyma. Quantitative or high-resolution computed tomography is used as a surrogate 
measure for assessment of disease progression. Different biological or molecular markers 
have been reported that reflect the mechanistic or pathogenic triad of inflammation, proteases, 
and oxidants and correspond to the different aspects of COPD histopathology. Similar to the 
pathogenic triad markers, genetic variations or polymorphisms have also been linked to COPD-
associated inflammation, protease–antiprotease imbalance, and oxidative stress. Furthermore, 
in recent years, there have been reports identifying aging-associated mechanistic markers as 
downstream consequences of the pathogenic triad in the lungs from COPD patients. For this 
review, the authors have limited their discussion to a review of mechanistic markers and genetic 
variations and their association with COPD histopathology and disease status.
Keywords: senescence, apoptosis, chronic obstructive pulmonary disease, bronchitis, 
emphysema
Introduction
Chronic obstructive pulmonary disease (COPD) manifests in two clinical phenotypes, 
bronchitis and emphysema.1,2 Chronic bronchitis is clinically defined as a productive 
cough on most days of a month for at least 3 months of a year in 2 or more consecutive 
years.3 Although cigarette smoking is the major cause for chronic bronchitis, other 
causes include air pollution and occupational exposures. These exposures introduce 
particulates and oxidants resulting in a common pathogenesis.2 Thus, the gross 
pathology and histology of chronic bronchitis is the same regardless of the etiology. 
Gross examination of lung tissue in a patient with chronic bronchitis shows thickened 
bronchial walls with luminal narrowing, and mucous plugging or mucopurulent 
debris within the airways. Microscopically, these gross findings correspond to goblet 
cell hyperplasia, thickening of the subepithelial basement membrane, bronchial 
wall fibrosis, and hyperplasia of the subepithelial seromucinous glands; classically 
defined by the Reid index (Figure 1).4 A chronic inflammatory infiltrate may also be 
present, but is not required, and squamous metaplasia of the respiratory epithelium 
can also be seen.
There are several types of emphysema that share in common destruction of alveolar 
walls with resultant enlargement of airspaces distal to terminal bronchioles. For the International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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purposes of this discussion, the Pratt classification5 will be 
used with the Thurlbeck classification6 given in parentheses. 
Centrilobular (centriacinar) emphysema is most commonly 
caused by cigarette smoking and is defined by   destruction 
of alveoli centered around the respiratory bronchiole and 
involving the proximal acinus.7 Gross examination shows 
punctuate areas of small airspace destruction, often associated 
with the deposition of pigment, which is   typically more 
  pronounced in the apices. Panlobular (panacinar) emphysema 
is caused by α1-antitrypsin deficiency (A1ATD); an inherited 
disorder involving chromosome 14. The gross pathology in 
panlobular emphysema is widespread destruction of alveolar 
tissue with dilation of small airspaces throughout the lungs. 
Destruction is accentuated at the lung bases, with less severe 
destruction in the upper lobes. The histomorphology of 
centrilobular and panlobular emphysema is similar. “Free-
floating” alveolar septa (Figure 2) are seen admixed with 
normal alveolar tissue in centrilobular emphysema. Normal 
alveolar tissue is not seen in panlobular.7 With progressive 
destruction, the formation of bulla (airspace dilation in excess 
of 1 mm) is often observed. These two forms of emphysema 
are broadly classified as diffuse, and they can cause impair-
ment of lung function.
Other types of emphysema include localized (distal 
acinar) and paracicatricial (irregular) emphysema. These 
focal forms do not result in impairment of lung function 
but can cause spontaneous pneumothoraces. Grossly, 
localized emphysema has one or two sites of severe lung 
parenchyma destruction, most commonly located at the 
extreme apex of the lung. Free-floating alveolar septa and 
bulla are again the histomorphologic correlate to the gross 
pathology.   Paracicatricial emphysema is defined as alveolar 
destruction surrounding foci of scarred lung tissue and can 
be seen in a wide variety of pulmonary disorders from healed 
foci of infection to the interstitial pneumonias as well as 
pneumoconioses.
Small airway obstruction has also been recognized as 
an important pathologic finding associated with COPD 
 ( Figure 3).8,9 Small airways disease includes respira-
tory   bronchiolitis and membranous bronchiolitis.10 The 
  histomorphology includes collections of macrophages contain-
ing smoker’s pigment within respiratory bronchiole lumina, 
alveolar ducts, and alveoli. A lymphocytic infiltrate within 
bronchiolar walls and peribronchiolar fibrosis with   bronchiolar 
metaplasia of alveolar septa (lambertosis) are additional 
  histologic features. Goblet cell metaplasia and mucostasis may 
also be seen within the membranous bronchioles.
Patients with COPD exhibit different characteristic 
  features of chronic bronchitis, emphysema, and/or asthma, 
A
B
Figure 1 Histologic features of chronic bronchitis. (A) A section of bronchiole wall 
with luminal accumulation of mucous, goblet cell hyperplasia, basement membrane 
thickening (arrow), and scattered mononuclear inflammatory cells. (B) A bronchial 
wall with squamous metaplasia of the luminal epithelium (arrow head) and hyperplasia 
of the subepithelial seromucinous glands (arrow).
Note: Hemotoxylin-eosin, original magnification ×200.
Figure 2 Histologic features of centrilobular emphysema. A section of lung tissue shows 
fragmented and “free-floating” alveolar septa (arrow) characteristic of emphysema.
Note: Hemotoxylin-eosin, original magnification ×200.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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but all exhibit clinical symptoms of airflow obstruction. 
The Global Initiative for Chronic Obstructive Lung   Disease 
(GOLD) has developed a COPD disease severity classification, 
stages I–IV, based primarily on pulmonary function tests 
(ie, forced vital capacity [FVC] and forced expiratory volume 
in 1 second [FEV1]). Pulmonary mechanics provide a clinical 
“snapshot” reflecting the combined effect of pathologic 
changes in all the affected lung compartments. Quantitative 
or high resolution computed tomography (CT) are surrogate 
measures for lung histology and are useful to assess airway 
wall thickening and emphysema.11,12 In the absence of actual 
tissue specimens, these two CT measurements provide an 
“ex vivo” type of pathological characterization. Similarly, 
CT assessment of airway wall thickness and emphysema 
each independently show associations with respiratory 
symptoms, such as dyspnea, cough, and wheezing, in COPD 
patients.11
Cigarette smoking is the primary environmental risk 
factor for COPD. In addition, other environmental (eg, 
wood smoke) and occupational exposures as well as 
genetics contribute to COPD pathogenesis. Consequently, 
pathologic changes and clinical symptoms are linked to 
the interaction of host factors with the environment. These 
interactions generate the pathologic triad of COPD: persistent 
inflammation, protease–antiprotease imbalance, and oxidative 
stress. This triad results in mucous/goblet cell metaplasia and 
hyperplasia, mucous hypersecretion, fibrosis, smooth-muscle 
alterations, and lung-tissue destruction.1 For this review, the 
authors have limited their discussion to a review of molecular 
markers and genetic host factors and their association with 
COPD histopathology and disease status. The Human 
Genome Project and the advancement of molecular biology 
and genetic analysis techniques, microarray analyses, and 
genome-wide association studies (GWASs) are leading to 
new discoveries of genetic variations that predispose to COPD 
susceptibility, lung function, and overall disease severity. 
Similar to the biomarkers, these genetic polymorphisms are 
linked to inflammation, protease–antiprotease imbalance, 
and oxidative stress.
Mechanistic triad: oxidative stress, 
protease–antiprotease imbalance, 
and inflammation
Oxidative stress
Chronic smoking exposes the respiratory tree and lungs to 
reactive oxygen species (ROS), resulting in oxidative stress 
and injury. This triggers production of other ROS and lipid 
peroxidation and subsequent pulmonary inflammation.13 
For example, increased expression of 4-hydroxy-2-
  nonenal, a product of lipid peroxidation, is present in 
both the   airway and alveolar epithelia of COPD patients.14 
Similarly, malondialdehyde (MDA), an end product of lipid 
peroxidation also increases in the blood of COPD patients 
and increases with severity of disease.15 Both tobacco and 
wood smoke exposure-associated COPD will trigger MDA 
production. Recent studies demonstrate that in smoke-
associated COPD patients, increases in blood MDA inversely 
correlate with changes in FEV1.16
Cigarette smoking also causes particulate deposits in the 
lungs with corresponding increases in tissue iron (by Perl’s 
Prussian blue staining).17 Compared with nonsmokers and 
healthy smokers, smokers with COPD have increased iron 
and ferritin and decreased transferrin in their bronchoalveolar 
lavage (BAL) fluid.17 The authors of this paper have recently 
reported similar findings in A1ATD patients.18 Importantly, 
Ghio et al demonstrated that cigarette smoke triggers ROS 
production by an iron-dependent mechanism.17 Smoking 
triggers airway and pulmonary inflammation, with an influx 
of inflammatory cells including macrophages and neutrophils. 
The authors of this paper and others have reported that 
neutrophil elastase (NE) will degrade endogenous iron 
storage or transport proteins, ferritin, transferrin (TF), and 
lactoferrin, and therefore, may increase the “free” iron 
burden. Investigators demonstrated the NE-induced cleavage 
of TF and lactoferrin in vitro.19 The authors of this paper have 
recently reported that NE degrades ferritin to release “free” 
iron that can be taken up by airway epithelial cells.18 NE 
degrades the ferritin very rapidly, and iron is taken up by the 
cells within a few hours. If there is redox-active iron in the 
Figure 3 Histologic features of small airways disease. A section of lung tissue shows 
accumulation of macrophages with smoker’s pigment (arrow) within and around a 
respiratory bronchiole (arrow head).
Note: Hemotoxylin-eosin, original magnification ×200.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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airway surface liquid, the iron can mediate the Haber–Weiss 
reaction, converting any superoxide and/or hydrogen 
peroxide released during a neutrophilic respiratory burst to 
the highly cytotoxic hydroxyl radical.20 Protease degradation 
of TF has been shown to result in iron-mediated hydroxyl 
radical formation and oxidative injury.21,22 Rodent models 
demonstrate that either cigarette smoke exposure or a single 
intratracheal installation of NE causes an increase in iron 
and ferritin in BAL and/or lungs of these animals, which can 
lead to ROS production and oxidative injury.17,18 In addition, 
genetic analyses with different cohorts of COPD subjects, 
both familial and nonfamilial cohorts as well as a smoker 
control group, demonstrated increased expression of iron 
regulatory protein 2 (IREB2 or IRP2) in the lungs of COPD 
patients compared with controls and a genetic association 
of IREB2 as a COPD susceptibility gene.23 Collectively, 
this information highlights the importance of iron-mediated 
oxidative stress in COPD pathogenesis.
Smoking increases the oxidative burden to the lungs. In 
COPD, this is compounded by alterations in the antioxidant 
defenses. Data mining of genetic studies reveals alterations 
in the nuclear factor-erythroid 2-related factor (Nrf2)-
mediated oxidative stress response pathway as well as the 
mitochondrial dysfunction pathway.24 Nrf2 is a transcription 
factor that regulates Phase II and antioxidant genes in 
response to oxidant stress.25,26 In COPD subjects compared 
with healthy smokers, there is decreased expression of heme 
oxygenase 1 (HMOX-1) and catalase, components of the Nrf2 
response pathway, and decreases in catalase and cytochrome 
C oxidase subunits, components of the mitochondrial 
dysfunction pathway. The HMOX-1 has a (GT)n dinucleotide 
repeat in the 5′-flanking region of the gene that has been 
reported to be highly polymorphic.27 In a Japanese population 
study, a HMOX-1 promoter polymorphism with 30 or 
more GT dinucleotide repeats is associated with increased 
susceptibility to emphysema in smokers.28 Furthermore, 
these investigators demonstrated that in response to oxidative 
stress, this polymorphism resulted in reduced transcriptional 
activity of the HMOX-1 gene decreasing the antioxidant 
capacity. Similarly, single-nucleotide polymorphisms 
(SNPs) in the glutathione-S-transferase (GST ) P1 gene have 
been associated with apical distribution of emphysema.29 
Interestingly, increased iron and ferritin levels have also been 
reported in the upper lobes of smokers,30 suggesting genetic 
variations along with iron-catalyzed oxidative stress/injury 
are important mechanisms in emphysema pathogenesis.
The association of emphysema with genetic variations 
in other antioxidant genes has also been reported. There are 
three forms of superoxide dismutase, SOD1 (Cu/Zn SOD), 
SOD2 (MnSOD) and SOD3 (extracellular SOD, ecSOD). 
SNPs in SOD3 have been reported to either protect or 
promote development of emphysema and COPD. In a study 
on populations of European descent, there was a higher 
frequency of the R213G (213Gly) variant of SOD3 in smokers 
who did not develop COPD, compared with individuals with 
COPD.31 Similarly, in a Danish population study, smokers 
expressing the R213G polymorphism in the SOD3 gene 
have a reduced risk of COPD development.32 However, other 
SOD3 polymorphisms are associated with increased risk of 
emphysema and reduced lung function. In two Copenhagen 
populations, two polymorphisms, E1 (rs8192287), in the 
5′ untranslated region of exon 1, and I1 (rs9192288), in 
the first intron, are linked to decreased lung function.33 
In both populations, individuals homozygous for these 
polymorphisms, that is having both E1 and I1 polymorphisms 
have lower FVC% predicted. The investigators also followed 
these individuals for 26 years to monitor for COPD-associated 
hospitalizations and death. Individuals homozygous for 
these polymorphisms had an increased risk of COPD 
hospitalizations compared with noncarrier smokers. A group 
of US investigators with different populations reported related 
findings to the study in Copenhagen. These investigators 
looked at the same three reported polymorphisms, E1, I1, 
and R213G in severe COPD subjects, smoking controls, 
and two family-based cohorts.34 Sorheim et al demonstrated 
that SOD3 SNPs E1 and I1 are associated with a higher 
incidence of CT-defined emphysema in one population, and 
only the E1 SNP is associated with more emphysema in a 
family-based population.34 The same family-based cohort 
also demonstrates that E1 SNP is associated with increased 
airway wall thickness. The investigators concluded that the 
E1 and I1 SOD3 SNPs are associated with CT-documented 
emphysema, but not COPD susceptibility.34
Markers of oxidant injury have also been linked to 
emphysema. One of these markers is the oxidation of 
guanine in deoxyribonucleic acid (DNA) or ribonucleic acid 
(RNA) to produce 8-oxo-7,8-dihydro-2′-deoxyguanosine 
(8OHdG) in DNA and 8-oxo-7,8-dihydroguanosine (8OHG) 
in RNA. Evaluation of emphysematous lungs from COPD 
patients with and without A1ATD reveals increased 
immunohistochemical staining for 8OHdG and 8OHG in the 
emphysematous lungs compared with non-COPD lungs.35 
In addition, lungs from A1ATD have increased oxidized 
DNA/RNA markers in alveolar macrophages and airway 
epithelial cells. These results suggest a role for nucleic acid 
oxidation in the pathophysiology of emphysema.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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The free radical theory of aging suggests that reactive 
oxygen species, modifiable by genetic and environmental 
factors (eg, smoking, pollutants), mediate aging-associated 
alterations in cells and tissues.36–39 Senescence and apoptosis 
are also linked with aging and COPD.40 Consequently, evidence 
of senescence markers and alveolar wall (ie, endothelial 
and/or epithelial) cell apoptosis in emphysematous lungs, 
implicates an aging paradigm important in COPD.41
Cigarette smoking has been implicated as a major 
risk factor for pulmonary cell senescence. Exposing lung 
fibroblasts and human alveolar epithelial cells to tobacco 
smoke in vitro induces senescence, a complete loss of 
replicative capacity, in both cell types.42,43 In the alveolar 
epithelial cells, senescence is characterized by increased 
senescence-associated β-galactosidase activity, accumulation 
of lipofuscin, and increased expression of the cyclin-
dependent kinase inhibitor, p21CIP1 (p21).43 Similar findings 
are also seen in the lung fibroblasts, as well as upregulation 
of a different cyclin-dependent kinase inhibitor, p16INK4a 
(p16), a known senescence biomarker.42 These reports 
were followed by studies using human lung emphysema 
tissues. Compared with healthy smokers and nonsmoker 
controls, emphysema patients have increased expression 
of senescence markers p16 and p21 in alveolar type II 
cells and alveolar endothelial cells.44 These investigators, 
using fluorescent in situ hybridization to assess telomere 
length, also demonstrated telomere shortening, as a marker 
of senescence, in the alveolar type II cells and endothelial 
cells. Similarly, in COPD patients compared with healthy 
smoker and nonsmoker controls, telomere shortening occurs 
in circulating leukocytes.45 A SNP in the BICD1 (bicaudal 
D homolog 1) gene is associated with human telomere 
length variations.46 Other SNPs were evaluated in several 
large cohorts by GWAS, comparing mild, moderate, and 
severe emphysema patients with controls.47 High-resolution 
CT (HRCT) was used to characterize the severity of the 
emphysema. This group also found a SNP in BICD1 that 
is significantly different between emphysema patients and 
controls and thus implicates this gene as an emphysema 
susceptibility gene.47
In addition to increased senescence in emphysematous 
lungs, there is increased apoptosis as part of the pathophysiology 
of emphysema and COPD. In particular, there is apoptosis of 
the structural cells, alveolar epithelial and endothelial cells. 
Apoptosis compounded by loss of proliferative capacity 
in these diseased lungs results in lung tissue loss and 
destruction (reviewed in Demedts et al48 and Morissette 
et al49). Emphysematous lungs, compared with those from 
healthy smokers and nonsmokers, have increased terminal 
transferase dUTP nick end labeling staining in alveolar septa 
in both alveolar epithelial and endothelial cells.50  The authors 
confirmed these findings with another immunohistochemical 
indicator of enhanced apoptosis, single-stranded DNA, 
demonstrating increased immunohistochemical staining in 
emphysematous lungs.50 Importantly, these investigators 
confirmed earlier in vitro and animal studies demonstrating 
decreased expression of vascular endothelial growth factor 
(VEGF) and VEGF R2 receptor in the pathogenesis of 
endothelial apoptosis in the emphysematous lungs.50 Other 
apoptosis markers are present in emphysematous lungs. There 
are increased p53 protein levels, Bax/Bcl-xL ratio and tumor 
necrosis factor-related apoptosis-inducing ligand receptors 1, 
2, and 3 protein levels in emphysematous lungs.51 Interestingly, 
different SNPs in the cell division cycle 6 homolog (CDC6) 
gene correspond to a gene-dosage effect in annual lung 
function decline in ex-smoking COPD patients.52 For example, 
SNP6 patients with Val/Val have a 2% annual rate of decline 
in FEV1% predicted, while patients with Ile/Ile have an 11% 
annual rate of decline.
Another link to apoptosis in COPD is the autophagic 
process. Autophagy is a highly regulated process by which 
internal organelles and proteins are degraded. Autophagic 
proteins Beclin 1 and LC3B mediate cigarette smoke 
extract-induced apopotsis of airway epithelial cells.53 In 
addition, by Western analysis, electron microscopy, and 
immunoflourescence, there is increased expression of the 
autophagic proteins LC3B-II/LC3B-I, Atg4, Atg5-artg12, 
and Atg7, as well as increased numbers of different stages 
of autophagic vacuoles in the lungs of COPD patients in all 
GOLD categories, with a corresponding increase in caspase 
3 activity, a marker of apoptosis in GOLD 3/4 patients.54
Inflammation
Inflammation in COPD is not a separate entity by itself 
but is integrally related to oxidative stress and protease–
antiprotease imbalance. Cigarette smoking and other inhaled 
pollutants can serve as a trigger or activator of inflammation, 
oxidative stress, and protease–antiprotease imbalance.
COPD patients compared with control subjects experience 
an overall heightened state of systemic inflammation 
reflected by biomarkers, such as cytokines and nitric oxide, 
which further increase with exacerbations.55 Similarly, 
bronchoalveolar lavage fluid and sputum also demonstrate 
increased inflammatory biomarkers such as cytokines, 
proteases, and soluble cytokine receptors.56 In addition, 
cytokine levels can increase with COPD disease severity.57International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Cigarette smoking and perhaps other types of smoke 
inhalation trigger an inflammatory response in the lungs 
resulting in the influx of different types of inflammatory 
cells. Neutrophils, macrophages, T lymphocytes, as well as 
eosinophils and mast cells, have all been associated with 
chronic bronchitis or COPD.58 It is interesting to note that there 
is a strong immunologic aspect to COPD that is characterized 
by T cell activation, proliferation into effector-type T cells, 
and then chemoattraction to the lung based on tissue-specific 
chemokine receptor and ligand expression. Furthermore, 
immune tolerance mechanisms, specifically failure to develop 
tolerance, correlates with COPD disease severity.59 Bronchial 
biopsies or surgical resection specimens of airways and lungs 
have been evaluated by immunohistochemistry to identify 
the infiltrating cells in these tissues. Bronchial biopsies from 
chronic bronchitis subjects with airflow obstruction (COPD) 
compared with normal subjects demonstrate increased 
numbers of CD3+ and CD8+ T cells, macrophages, and 
increased HLA-DR expression.60 Importantly, these 
investigators demonstrate an inverse relationship between 
the number of CD8+ T cells, neutrophils, and eosinophils 
with FEV1% predicted in the chronic bronchitis patients. 
Similarly, both airways and lungs from smokers with COPD, 
compared with normal subjects, have increased CD8+ T cells 
in the lung parenchyma, pulmonary arteries, and peripheral 
airways.61,62 Importantly, the number of CD8+ T cells in 
the lung parenchyma and pulmonary arteries of the COPD 
patients negatively correlates with FEV1% predicted.61 
Furthermore, compared with control subjects, COPD subjects 
have increased expression of CXCR3+ cells, important in a 
Th1-type of response, which are also CD8+, in the airway 
epithelium and submucosa and increased expression of the 
CXCR3-ligand CXCL10 on the bronchiolar epithelium.63 
These studies highlight the importance of T cells in 
progression of COPD.
Neutrophils are also an important infiltrating inflammatory 
cell in COPD. Bronchial biopsies from GOLD stage III and 
IV COPD patients (severe/very severe) compared with 
healthy nonsmokers and healthy smokers, demonstrate 
increased expression of the chemokine CCL5, leukocyte 
chemotactic chemokine, in the airway epithelium and 
a corresponding increase in neutrophils in the airway 
submucosa.64 Interestingly, based on HRCT scoring of 
emphysema, an SNP in the CCL5 gene has been associated 
with milder emphysema.65 The submucosal neutrophils 
also have increased expression of CD11b and CD44, which 
promote adhesiveness in severe/very severe COPD.64 The 
severity of COPD is also aggravated by acute exacerbations, 
which are often associated with microbial infections and 
neutrophilic inflammation.66 Bronchial biopsies from COPD 
patients with acute severe exacerbations were compared 
with biopsies from stable COPD patients as well as normal 
nonsmoker, nonatopic control subjects. Compared with 
stable COPD and control subjects, patients with acute severe 
exacerbations have neutrophilia and, by in situ hybridization, 
increased mRNA expression of CXCL5 (epithelial derived 
neutrophil attractant-78), CXCL8 (IL-8), CXCR1, and 
CXCR2.67 In addition, a SNP in the CCL1 gene, a chemokine 
that is chemotactic for leukocytes, is significantly associated 
with the frequency of acute severe COPD exacerbations.68 
Furthermore, prospectively, these investigators demonstrated 
this polymorphism is significantly associated with an 
increased risk of death due to acute exacerbations. 
Consequently, they demonstrated a “gene–dosage effect” 
between subjects that are heterozygous versus homozygous 
for the polymorphism.68 Altogether, these studies highlight 
the key role of inflammatory cells, particularly neutrophils, 
macrophages, and T cells, in mediating progression of 
COPD.
Cigarette smoking is a trigger for senescence. One of 
the sequelae of senescence is the development of a pro-
inflammatory phenotype.69 In lung tissues from COPD 
patients compared with healthy smoker and nonsmoking 
control subjects, nuclear factor (NF)-κΒ activation is 
increased in senescent alveolar type II cells.70 In addition, 
compared with nonsmoking controls, there is decreased 
sirtuin deacetylase (SIRT1) protein expression, an anti-
inflammatory and anti-aging protein that negatively regulates 
transcription factors such as NF-κΒ, in the lungs of 
COPD patients.71 Thus, senescent cells may propagate the 
inflammatory response in COPD. Importantly, alveolar and 
endothelial senescence markers, p16 and p21, are positively 
correlated with airflow obstruction (FEV1% predicted)44 
and shortened telomere length in leukocytes from COPD 
patients with hypoxemia.45
Protease–antiprotease imbalance
In a simplistic sense, emphysema is caused by the 
imbalance of proteases and antiproteases that results in lung 
parenchymal destruction.72 The classic example is A1ATD, 
where unopposed neutrophil elastase has deleterious effects 
on the lungs. However, in the overall pathogenesis, it is the 
interactions between ROS and proteases or antiproteases that 
trigger this imbalance. Smoke exposure from cigarettes or 
biomass exposure from indoor fires can inactivate endogenous 
antiproteases,73 as well as trigger an acute pulmonary response International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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that activates resident alveolar macrophages and promotes 
neutrophil influx into lungs. As the smoke exposure continues 
and becomes more chronic, there is continued accumulation 
of macrophages, neutrophils, and CD8+ T cells in the 
lungs.74 The macrophages and neutrophils release a variety 
of proteases, including neutrophil elastase, proteinase 3, 
matrix metalloproteinases (MMPs), and cathepsins. These 
proteinases “support” each other by activating each other or 
inhibiting their endogenous inhibitors, such as neutrophil 
elastase inhibiting tissue inhibitors of MMPs, and MMPs 
degrading α1-antitrypsin.74 These proteinases cleave 
components of the extracellular matrix, elastin fibers and 
collagen, generating elastin fragments or collagen-derived 
peptides such as proline-glycine-proline, which have been 
shown to be chemotactic for monocytes, the precursor cell 
for macrophages75 or neutrophils.76 Collectively, chemotactic 
peptide fragments perpetuate macrophage and neutrophil 
accumulation and lung destruction.
Genetic factors also regulate protease activity in the 
lung and emphysema development. MMP12 knockout mice 
are protected from cigarette-smoke-induced emphysema.77 
Genetic studies in large COPD-related cohorts, including 
a family-based COPD cohort, identified a SNP in MMP12 
that protects lung function and reduces the risk of COPD 
in adult smokers.78 In contrast, two studies from Japan that 
used CT or HRCT to characterize the presence and severity 
of emphysema identified an SNP in MMP9 that is associated 
with smoking-induced emphysema development.79,80 In 
addition to MMPs, SERPINE2, an inhibitor of MMP 
activation and extracellular matrix destruction, has been 
linked to COPD as a potential susceptibility gene.81,82 Both 
studies used large case–control cohorts as well as family-
based cohorts to demonstrate the association of SERPINE2 
SNPs with COPD. DeMeo et al proposed a gene-by-smoking 
interaction for this gene.81
Summary
The unique histopathology of COPD is driven by interactions 
between host factors and environmental exposures. Basic and 
translational research have provided important discoveries 
concerning these interactions in COPD, resulting in the devel-
opment of biomarkers reflecting protease injury, oxidative 
stress, inflammation, senescence, and apoptosis (Figure 4). 
The breadth of pathological variability in COPD presents 
a challenge for clinicians. Unique gene and environmental 
interactions may provide critical new insights explaining indi-
vidual manifestations of disease and opportunities to improve 
outcomes for patients.
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